Inovio Pharmaceuticals Inc Stock Nyse
Equities
INO
US45773H2013
Biotechnology & Medical Research
Sales 2024 * | 348K 479K | Sales 2025 * | 19.8M 27.26M | Capitalization | 248M 342M |
---|---|---|---|---|---|
Net income 2024 * | -121M -167M | Net income 2025 * | -108M -149M | EV / Sales 2024 * | 714 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.5 x |
P/E ratio 2024 * |
-2.17
x | P/E ratio 2025 * |
-3.01
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.4% |
Latest transcript on Inovio Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
Chief Tech/Sci/R&D Officer | - | 07-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
1st Jan change | Capi. | |
---|---|---|
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |